Full text not available from this repository.

Abstract

The revolution of induced pluripotent stem cell (iPSC) technology provides a platform for development of cell therapy, disease modeling and drug discovery. Recent technological advances now allow us to reprogram a patient's somatic cells into induced pluripotent stem cells (iPSCs). Together with methods to differentiate these iPSCs into disease-relevant cell types, we are now able to model disease in vitro using iPSCs. Importantly, this represents a robust in vitro platform using patient-specific cells, providing opportunity for personalized precision medicine. Here we provide a review of advances using iPSC for drug development, and discuss the potential and limitations of iPSCs for drug discovery in neurodegenerative and ocular diseases. Emerging technologies that can facilitate the search for new drugs by assessment using in vitro disease models will also be discussed, including organoid differentiation, organ-on-chip, direct reprogramming and humanized animal models.

Item Type:	Article
Authors/Creators:	Hung, SSC and Khan, S and Lo, CY and Hewitt, AW and Wong, RCB
Keywords:	Disease modeling, drug discovery, high throughput screening, induced pluripotent stem cells, organ-on-chip, organoid
Journal or Publication Title:	Pharmacology and Therapeutics
Publisher:	Pergamon-Elsevier Science Ltd
ISSN:	0163-7258
DOI / ID Number:	10.1016/j.pharmthera.2017.02.026
Copyright Information:	Copyright 2017 Elsevier Inc.
Related URLs:	Google Scholar: Hewitt, AW UTAS Profile: Hewitt, AW
Item Statistics:	View statistics for this item

Actions (login required)

Item Control Page